2016 PREVIEW: India - Compliance, IPR Clarity And Price Pressures
This article was originally published in PharmAsia News
Executive Summary
If 2015 was a year the Indian industry would rather forget in terms of GMP-based run-ins with the US FDA, 2016 may well see enhanced top management involvement and investments in compliance-related issues.